The US Food and Drug Administration have put its report on its website. Some of the products of Indian medicine major, Ranbaxy do not conform to the safety standards set by the inspection agency of US. It has banned 31 drugs produced by Ranbaxy. The agency had not mentioned the name of Daiichi Sankyo, the Japanese firm which is in the process to buy the Indian medicine company in its report

The medicine produced at the Dewas plant and Pounta Sahib plants are found defected. The products of other plants of Ranbaxy met the standards set by the agency. Ranbaxy has about 11 plants around the world and isa major drug supplier to the US market. The US Food and Drug Administration have warned Ranbaxy on safety standards. Meanwhile, Ranbaxy is disappointed by the behavior of US drug agency as the company is responding to the quarries of agency since two years.

The shares of company declined to 7% on the BSE following the warnings by US agency.